"Timing is just about right: COVID-19 does not only act as a catalyst for telemedicine and triage solutions, but also for Digital Therapeutics (hereafter DTx) solutions as their practicability is immune to current COVID-19 related restrictions. Recent spikes in usage of different DTx solutions across geographies and indications prove this.
In the aftermath of COVID-19, any measures boosting human resilience to such external health shocks will increase in significance. One personal example: poorly managed Type 1 diabetics with consistently elevated blood sugar levels are at higher risk of developing serious complications from COVID-19 (Link). The same applies to adjacent indications such as Type 2 diabetes and obesity. Patients with often preventable conditions such as Type 2 diabetes and with poorly managed chronic diseases such as Type 1 diabetes are more prone to an adverse course of disease. This highlights the essence of chronic disease management, reversal (if possible) or prevention in the first place..."
Lire la suite
Digital Therapeutics: a bumpy road to commercialisation
Medium, 29/05/2020
Partagé par :
Beesens TEAM